Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody therapies - Vaccinex/Five Prime

Drug Profile

Research programme: monoclonal antibody therapies - Vaccinex/Five Prime

Alternative Names: Anti-CXCL13 monoclonal antibody; Anti-VEGF1/2 monoclonal antibody; VX-5; VX-60; VX-70; VX5/5261

Latest Information Update: 18 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaccinex
  • Class Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL13 inhibitors; Immunomodulators; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Discontinued Bacterial infections; Cancer; Viral infections

Most Recent Events

  • 18 Apr 2018 Preclinical development for Autoimmune disorders is ongoing (Vaccinex pipeline, April 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 19 Mar 2015 Monoclonal antibody therapies licensed to Five Prime therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top